Researchers turned white blood cells called neutrophils into drug-smuggling “neutrobots,” which penetrated the blood-brain barrier to treat brain cancer in mice.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

The oncologist developed lifesaving childhood leukemia treatments and revolutionized chemotherapy.

Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

Strategies to trick, manipulate, and direct the evolution of tumors

The Vanderbilt University professor was awarded a Nobel Prize for his discovery of epidermal growth factor.

Colorectal tumor cells limit their DNA repair in response to a targeted therapy, giving them a greater chance to develop resistance to the drug.

A study of 11 drugs now in clinical trials suggests they do kill cancer cells—but through a different mechanism than indicated in previous research.

Fly avatars bearing multiple genetic changes akin to those of a cancer patient lead to a tailor-made treatment that has shrunk the patient’s tumors.

The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.

Loxo focuses on cancer treatments based on tumor genetics, which will contribute to Lilly’s push in the cancer drug space.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.

A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.

Researchers use several different strategies to deliver a one-two punch.

Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.

The public cancer center is criticized for allegedly devoting at least $1.5 million to remodeling an executive suite.

Results of breast cancer drug trials are regularly spun to conceal bias and make the drugs seem more effective or less toxic than they really are.

A Texas cancer institute is taking a second look at the largest grant it ever awarded after concerns were raised that the proposal never received proper scientific review.